Lacosamide Injection
Product Images NDC 65219-204

7 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 65219-204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical Structure (Image 01)
Chemical structure of lacosamide, showing its molecular configuration with key functional groups including an amide, a methoxy group, and a phenyl ring.*
FDA Label Image

Figure 1 (Image 02)

Figure 1 (Image 02)
A bar chart presenting seizure reduction percentages from baseline across three clinical studies comparing placebo and Lacosamide at different doses. The vertical axis shows median percent seizure reduction with values from 0% to 45%, while the horizontal axis separates results by study and treatment group. Each study displays higher seizure reduction for Lacosamide versus placebo, with sample sizes and doses labeled below each bar.*
FDA Label Image

Figure 2 (Image 03)

Figure 2 (Image 03)
A line chart showing responder rate improvement versus percent of patients for Lacosamide injection at doses 200 mg/day, 400 mg/day, and 600 mg/day compared to placebo. The chart plots responder rate from -100% to 100% improvement against the cumulative percentage of patients from 100% to 0%, illustrating dose-response trends.*
FDA Label Image

Fresenius Kabi Logo (Image 04)

FDA Label Image

Fresenius Kabi Logo (Lac07 0004 05)

FDA Label Image

Lacos-label-01.jpg (Lacos Label 01)

Lacos-label-01.jpg (Lacos Label 01)
Label of Lacosamide Injection, USP 200 mg per 20 mL (10 mg per mL), single-dose vial for intravenous use only. The label indicates a 20 mL volume and is marked Rx only. It includes storage instructions at 20°C to 25°C with permitted excursions, and a warning to keep out of reach of children. The labeler is Fresenius Kabi USA, LLC, Lake Zurich, IL, with NDC 65219-204-01.*
FDA Label Image

Lacos-label-02.jpg (Lacos Label 02)

Lacos-label-02.jpg (Lacos Label 02)
Label for Lacosamide Injection, USP 200 mg per 20 mL (10 mg/mL) intravenous injection. The label indicates 10 single-dose vials of 20 mL solution for infusion, each containing 200 mg lacosamide. Manufactured by Fresenius Kabi USA, LLC, with storage instructions and inactive ingredient details included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.